Literature DB >> 22319455

The mitochondrial chaperone protein TRAP1 mitigates α-Synuclein toxicity.

Erin K Butler1, Aaron Voigt, A Kathrin Lutz, Jane P Toegel, Ellen Gerhardt, Peter Karsten, Björn Falkenburger, Andrea Reinartz, Konstanze F Winklhofer, Jörg B Schulz.   

Abstract

Overexpression or mutation of α-Synuclein is associated with protein aggregation and interferes with a number of cellular processes, including mitochondrial integrity and function. We used a whole-genome screen in the fruit fly Drosophila melanogaster to search for novel genetic modifiers of human [A53T]α-Synuclein-induced neurotoxicity. Decreased expression of the mitochondrial chaperone protein tumor necrosis factor receptor associated protein-1 (TRAP1) was found to enhance age-dependent loss of fly head dopamine (DA) and DA neuron number resulting from [A53T]α-Synuclein expression. In addition, decreased TRAP1 expression in [A53T]α-Synuclein-expressing flies resulted in enhanced loss of climbing ability and sensitivity to oxidative stress. Overexpression of human TRAP1 was able to rescue these phenotypes. Similarly, human TRAP1 overexpression in rat primary cortical neurons rescued [A53T]α-Synuclein-induced sensitivity to rotenone treatment. In human (non)neuronal cell lines, small interfering RNA directed against TRAP1 enhanced [A53T]α-Synuclein-induced sensitivity to oxidative stress treatment. [A53T]α-Synuclein directly interfered with mitochondrial function, as its expression reduced Complex I activity in HEK293 cells. These effects were blocked by TRAP1 overexpression. Moreover, TRAP1 was able to prevent alteration in mitochondrial morphology caused by [A53T]α-Synuclein overexpression in human SH-SY5Y cells. These results indicate that [A53T]α-Synuclein toxicity is intimately connected to mitochondrial dysfunction and that toxicity reduction in fly and rat primary neurons and human cell lines can be achieved using overexpression of the mitochondrial chaperone TRAP1. Interestingly, TRAP1 has previously been shown to be phosphorylated by the serine/threonine kinase PINK1, thus providing a potential link of PINK1 via TRAP1 to α-Synuclein.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22319455      PMCID: PMC3271059          DOI: 10.1371/journal.pgen.1002488

Source DB:  PubMed          Journal:  PLoS Genet        ISSN: 1553-7390            Impact factor:   5.917


  85 in total

1.  Genetic modifiers of tauopathy in Drosophila.

Authors:  Joshua M Shulman; Mel B Feany
Journal:  Genetics       Date:  2003-11       Impact factor: 4.562

Review 2.  Epidemiology of neurodegeneration.

Authors:  Richard Mayeux
Journal:  Annu Rev Neurosci       Date:  2003-01-24       Impact factor: 12.449

3.  Parkin deficiency disrupts calcium homeostasis by modulating phospholipase C signalling.

Authors:  Anna Sandebring; Nodi Dehvari; Monica Perez-Manso; Kelly Jean Thomas; Elena Karpilovski; Mark R Cookson; Richard F Cowburn; Angel Cedazo-Mínguez
Journal:  FEBS J       Date:  2009-08-03       Impact factor: 5.542

4.  Environmental risk factors and Parkinson's disease: a case-control study in Taiwan.

Authors:  H H Liou; M C Tsai; C J Chen; J S Jeng; Y C Chang; S Y Chen; R C Chen
Journal:  Neurology       Date:  1997-06       Impact factor: 9.910

5.  Tumor necrosis factor-associated protein 1 (TRAP-1) protects cells from oxidative stress and apoptosis.

Authors:  N Montesano Gesualdi; G Chirico; G Pirozzi; E Costantino; M Landriscina; F Esposito
Journal:  Stress       Date:  2007-11       Impact factor: 3.493

6.  Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain.

Authors:  Latha Devi; Vijayendran Raghavendran; Badanavalu M Prabhu; Narayan G Avadhani; Hindupur K Anandatheerthavarada
Journal:  J Biol Chem       Date:  2008-02-01       Impact factor: 5.157

7.  Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein.

Authors:  Merja Lakso; Suvi Vartiainen; Anu-Maarit Moilanen; Jouni Sirviö; James H Thomas; Richard Nass; Randy D Blakely; Garry Wong
Journal:  J Neurochem       Date:  2003-07       Impact factor: 5.372

8.  TDP-43-mediated neuron loss in vivo requires RNA-binding activity.

Authors:  Aaron Voigt; David Herholz; Fabienne C Fiesel; Kavita Kaur; Daniel Müller; Peter Karsten; Stephanie S Weber; Philipp J Kahle; Till Marquardt; Jörg B Schulz
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

9.  Genome-wide screen for modifiers of ataxin-3 neurodegeneration in Drosophila.

Authors:  Julide Bilen; Nancy M Bonini
Journal:  PLoS Genet       Date:  2007-10       Impact factor: 5.917

10.  Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function.

Authors:  Vanessa A Morais; Patrik Verstreken; Anne Roethig; Joél Smet; An Snellinx; Mieke Vanbrabant; Dominik Haddad; Christian Frezza; Wim Mandemakers; Daniela Vogt-Weisenhorn; Rudy Van Coster; Wolfgang Wurst; Luca Scorrano; Bart De Strooper
Journal:  EMBO Mol Med       Date:  2009-05       Impact factor: 12.137

View more
  58 in total

Review 1.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

2.  Hsp90 regulation of mitochondrial protein folding: from organelle integrity to cellular homeostasis.

Authors:  Dario C Altieri
Journal:  Cell Mol Life Sci       Date:  2012-09-30       Impact factor: 9.261

3.  Number and Brightness analysis of alpha-synuclein oligomerization and the associated mitochondrial morphology alterations in live cells.

Authors:  N Plotegher; E Gratton; L Bubacco
Journal:  Biochim Biophys Acta       Date:  2014-02-20

4.  Mitochondrial chaperone TRAP1 activates the mitochondrial UPR and extends healthspan in Drosophila.

Authors:  Rehan M Baqri; Arielle V Pietron; Rewatee H Gokhale; Brittany A Turner; Laurie S Kaguni; Alexander W Shingleton; Sam Kunes; Kyle E Miller
Journal:  Mech Ageing Dev       Date:  2014-09-26       Impact factor: 5.432

Review 5.  Physicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs).

Authors:  Francois-Xavier Theillet; Andres Binolfi; Tamara Frembgen-Kesner; Karan Hingorani; Mohona Sarkar; Ciara Kyne; Conggang Li; Peter B Crowley; Lila Gierasch; Gary J Pielak; Adrian H Elcock; Anne Gershenson; Philipp Selenko
Journal:  Chem Rev       Date:  2014-06-05       Impact factor: 60.622

Review 6.  The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease.

Authors:  Noémie Cresto; Camille Gardier; Francesco Gubinelli; Marie-Claude Gaillard; Géraldine Liot; Andrew B West; Emmanuel Brouillet
Journal:  Eur J Neurosci       Date:  2018-10-24       Impact factor: 3.386

7.  Differential submitochondrial localization of PINK1 as a molecular switch for mediating distinct mitochondrial signaling pathways.

Authors:  Dana Fallaize; Lih-Shen Chin; Lian Li
Journal:  Cell Signal       Date:  2015-10-06       Impact factor: 4.315

8.  Cellular Signature of SIL1 Depletion: Disease Pathogenesis due to Alterations in Protein Composition Beyond the ER Machinery.

Authors:  Andreas Roos; Laxmikanth Kollipara; Stephan Buchkremer; Thomas Labisch; Eva Brauers; Christian Gatz; Chris Lentz; José Gerardo-Nava; Joachim Weis; René P Zahedi
Journal:  Mol Neurobiol       Date:  2015-10-14       Impact factor: 5.590

Review 9.  Alterations in the E3 ligases Parkin and CHIP result in unique metabolic signaling defects and mitochondrial quality control issues.

Authors:  Britney N Lizama; Amy M Palubinsky; BethAnn McLaughlin
Journal:  Neurochem Int       Date:  2017-08-26       Impact factor: 3.921

10.  Deletion of the mitochondrial chaperone TRAP-1 uncovers global reprogramming of metabolic networks.

Authors:  Sofia Lisanti; Michele Tavecchio; Young Chan Chae; Qin Liu; Angela K Brice; Madhukar L Thakur; Lucia R Languino; Dario C Altieri
Journal:  Cell Rep       Date:  2014-07-31       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.